Plus Therapeutics will provide a business update and host a conference call on June 26, 2025.
Quiver AI Summary
Plus Therapeutics, Inc. announced that it will provide a business update on June 26, 2025, before the market opens. The management team will host a conference call and webcast at 9:00 a.m. ET to discuss further details. Participants are encouraged to pre-register for the call, and a replay will be available afterward on the company's website. Plus Therapeutics is a Houston-based clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for challenging central nervous system cancers, specifically targeting conditions like leptomeningeal metastases and recurrent glioblastoma. The company utilizes advanced technologies to improve treatment outcomes and has established a supply chain for potential product commercialization. More information can be found on their website.
Potential Positives
- Plus Therapeutics is set to provide a significant business update, indicating ongoing progress and transparency with investors.
- The upcoming conference call and webcast will foster direct communication between management and stakeholders, enhancing investor relations.
- The company's focus on developing targeted radiotherapeutics for CNS cancers could highlight its commitment to addressing unmet medical needs in a critical healthcare sector.
- Strategic partnerships for supply chain development demonstrate the company's proactive approach to ensuring successful product development and commercialization.
Potential Negatives
- Announcement of a business update may indicate potential concerns or a lack of progress regarding the company's pipeline, especially if no significant new developments are shared during the call.
- The company's clinical-stage status suggests it has not yet achieved market approval, which could reflect potential risks and challenges in advancing its products to commercialization.
- Participants are encouraged to pre-register for the call, which may suggest that the company anticipates a high level of interest or need for clarification regarding its business status.
FAQ
When will Plus Therapeutics provide a business update?
Plus Therapeutics will provide a business update on Thursday, June 26, 2025, before the market opens.
What time is the conference call for Plus Therapeutics?
The conference call will take place at 9:00 a.m. ET on June 26, 2025.
How can I access the webcast for the business update?
The webcast can be accessed at https://edge.media-server.com/mmc/p/97egitn8.
Where can I find the replay of the conference call?
The replay will be available on the Company’s website under the ‘For Investors’ section after the live call.
What is Plus Therapeutics’ focus in drug development?
Plus Therapeutics focuses on developing targeted radiotherapeutics for central nervous system cancers, particularly leptomeningeal metastases and recurrent glioblastoma.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PSTV Hedge Fund Activity
We have seen 10 institutional investors add shares of $PSTV stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC removed 560,905 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $532,915
- HRT FINANCIAL LP added 102,065 shares (+inf%) to their portfolio in Q1 2025, for an estimated $96,971
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 80,505 shares (+inf%) to their portfolio in Q1 2025, for an estimated $76,487
- VIRTU FINANCIAL LLC added 40,030 shares (+inf%) to their portfolio in Q1 2025, for an estimated $38,032
- UBS GROUP AG added 33,437 shares (+inf%) to their portfolio in Q1 2025, for an estimated $31,768
- GROUND SWELL CAPITAL, LLC added 13,657 shares (+inf%) to their portfolio in Q1 2025, for an estimated $12,975
- ASHTON THOMAS PRIVATE WEALTH, LLC removed 12,913 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $14,849
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) --
Plus Therapeutics, Inc.
(Nasdaq:
PSTV
) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, June 26, 2025 before the market open. Plus Therapeutics’ management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details.
Webcast and Conference Call
Date/Time: | Thursday, June 26, 2025 @ 9:00 AM ET | |
Webcast: | https://edge.media-server.com/mmc/p/97egitn8 | |
Dial-in Link: | https://register-conf.media-server.com/register/BI66b197347e6041329ab814378ea34059 | |
Participants are encouraged to pre-register any time before the call through the dial-in link. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company’s website under the ‘For Investors’ section. The webcast will be available on the Company’s website for 90 days following the live call.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit
https://www.plustherapeutics.com
.
Investor Contact
CORE IR
investor@plustherapeutics.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
